Published in Proc Natl Acad Sci U S A on July 18, 1995
Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med (1998) 2.76
Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs (2010) 1.89
Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci U S A (2009) 1.74
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica (2014) 1.43
Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell (2002) 1.39
The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci U S A (1997) 1.36
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol (2015) 1.17
Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol (2015) 1.09
T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther (2013) 1.07
Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun (2012) 0.98
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs (2015) 0.97
Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol (2014) 0.97
Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications. Front Oncol (2014) 0.96
A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem (2015) 0.95
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). Oncoimmunology (2012) 0.91
The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. PLoS One (2012) 0.91
Novel immunotherapies for hematologic malignancies. Immunol Rev (2015) 0.90
Investigational immunotherapeutics for B-cell malignancies. J Clin Oncol (2010) 0.88
Bi-specific aptamers mediating tumor cell lysis. J Biol Chem (2011) 0.87
Insight to drug delivery aspects for colorectal cancer. World J Gastroenterol (2016) 0.86
Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications. Oncoimmunology (2014) 0.85
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Rev Clin Pharmacol (2013) 0.84
The making of bispecific antibodies. MAbs (2017) 0.84
Recombinant GPI-anchored TIMP-1 stimulates growth and migration of peritoneal mesothelial cells. PLoS One (2012) 0.81
Are BiTEs the "missing link" in cancer therapy? Oncoimmunology (2015) 0.81
Recombinant TIMP-1-GPI inhibits growth of fibrosarcoma and enhances tumor sensitivity to doxorubicin. Target Oncol (2013) 0.80
Blinatumomab for the treatment of acute lymphoblastic leukemia. Invest New Drugs (2015) 0.80
One-step enzymatic modification of the cell surface redirects cellular cytotoxicity and parasite tropism. ACS Chem Biol (2014) 0.80
Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins. Front Immunol (2016) 0.80
Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J (2016) 0.79
Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia. Mol Ther (2015) 0.78
Design and applications of bispecific heterodimers: molecular imaging and beyond. Mol Pharm (2014) 0.78
CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. MAbs (2016) 0.78
Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma. J Clin Oncol (2016) 0.77
Construction, expression, and characterization of a recombinant immunotoxin targeting EpCAM. Mediators Inflamm (2015) 0.76
Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer (2015) 0.75
Rapid detection of hepatitis B virus surface antigen by an agglutination assay mediated by a bispecific diabody against both human erythrocytes and hepatitis B virus surface antigen. Clin Vaccine Immunol (2007) 0.75
An engineered genetic selection for ternary protein complexes inspired by a natural three-component hitchhiker mechanism. Sci Rep (2014) 0.75
Engineering tandem single-chain Fv as cell surface reporters with enhanced properties of fluorescence detection. Protein Eng Des Sel (2015) 0.75
Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth. Theranostics (2017) 0.75
A New Agent in the Strategy to Cure AIDS. Mol Ther (2016) 0.75
Detection of a phosphorylated glycine-serine linker in an IgG-based fusion protein. MAbs (2016) 0.75
Solid-phase bioconjugation of heterobifunctional adaptors for versatile assembly of bispecific targeting ligands. Bioconjug Chem (2014) 0.75
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds. Front Immunol (2017) 0.75
A strategy to identify linker-based modules for the allosteric regulation of antibody-antigen binding affinities of different scFvs. MAbs (2017) 0.75
A new method for predicting signal sequence cleavage sites. Nucleic Acids Res (1986) 37.19
Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature (1988) 19.07
pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res (1990) 12.75
Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A (1988) 6.14
Single-chain antigen-binding proteins. Science (1988) 5.29
Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci U S A (1989) 3.99
Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet (1994) 3.24
"Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A (1993) 2.91
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res (1992) 2.83
Hybrid antibodies can target sites for attack by T cells. Nature (1985) 2.36
The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol (1987) 2.04
Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature (1985) 2.00
Selection and coamplification of heterologous genes in mammalian cells. Methods Enzymol (1990) 1.75
A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry (1990) 1.60
Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci U S A (1990) 1.57
The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer (1986) 1.47
Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci U S A (1986) 1.40
Formation of a bispecific antibody by the use of leucine zippers. J Immunol (1992) 1.37
A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci U S A (1993) 1.35
Preliminary trial of specific targeting therapy against malignant glioma. Lancet (1990) 1.20
Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells. EMBO J (1991) 1.13
Construction, expression, and activity of a bivalent bispecific single-chain antibody. J Biol Chem (1994) 1.06
Targeted cytotoxic cells in human peripheral blood lymphocytes. J Immunol (1990) 1.02
Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science (1994) 0.99
Expression of functional antibody Fv and Fab fragments in Escherichia coli. Methods Enzymol (1989) 0.97
Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J Immunol (1994) 0.95
Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice. J Immunol (1987) 0.94
Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer Suppl (1992) 0.94
The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy. J Immunol (1994) 0.90
Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2. J Natl Cancer Inst (1993) 0.89
Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J Immunol (1991) 0.89
Adhesion receptors in lymphocyte activation. Curr Opin Immunol (1994) 0.87
Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol (1991) 0.87
Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur J Immunol (1991) 0.87
Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells. J Immunol (1991) 0.86
Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth. J Immunol (1991) 0.85
Cell-mediated cytotoxic mechanisms. Curr Opin Immunol (1994) 0.84
Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model. Cancer Res (1991) 0.82
Bispecific IgG and IL-2 therapy of a syngeneic B-cell lymphoma in immunocompetent mice. Int J Cancer Suppl (1992) 0.78
Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med (2000) 6.98
Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci U S A (1999) 3.74
Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer (1988) 3.66
MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A (1989) 2.82
Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol (1997) 2.28
Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet (1992) 2.21
Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst (1993) 2.14
Nck, a melanoma cDNA encoding a cytoplasmic protein consisting of the src homology units SH2 and SH3. Nucleic Acids Res (1990) 2.12
Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. J Biol Chem (1994) 2.08
De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci U S A (1989) 1.90
Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet (1996) 1.84
Molecular mechanisms in down-regulation of tumor necrosis factor expression. Proc Natl Acad Sci U S A (1990) 1.83
Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int (1993) 1.80
Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol (1991) 1.76
Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology (1995) 1.72
p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene (1993) 1.62
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood (2000) 1.55
Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res (1987) 1.52
ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res (2001) 1.48
The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer (1986) 1.47
p53 in non-small-cell lung cancer. J Natl Cancer Inst (1994) 1.46
Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res (1999) 1.43
Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol (1991) 1.42
Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer (1987) 1.41
Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A (1987) 1.36
Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother (1994) 1.34
Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions. Mol Cell Biol (2001) 1.32
Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer (1991) 1.31
Genomic organization of the melanoma-associated glycoprotein MUC18: implications for the evolution of the immunoglobulin domains. Proc Natl Acad Sci U S A (1993) 1.31
Direct demonstration of an HLA-DR allotypic determinant on the low molecular weight (beta) subunit using a mouse monoclonal antibody specific for DR3. J Exp Med (1982) 1.29
Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum (1991) 1.28
Involvement of the cytotoxic/suppressor T-cell subset in liver tissue injury of patients with acute and chronic liver diseases. Gastroenterology (1983) 1.26
Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res (1991) 1.25
The monoclonal CD4 antibody M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: an approach to postexposure prophylaxis. Proc Natl Acad Sci U S A (1992) 1.24
The cellular receptor (CD4) of the human immunodeficiency virus is expressed on neurons and glial cells in human brain. J Exp Med (1987) 1.23
Surface antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse tissue origin. Eur J Immunol (1981) 1.21
In vitro desensitization to lipopolysaccharide suppresses tumour necrosis factor, interleukin-1 and interleukin-6 gene expression in a similar fashion. Immunology (1992) 1.20
Organization, sequence and expression of the HLA-B27 gene: a molecular approach to analyze HLA and disease associations. Immunobiology (1985) 1.20
T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia (2012) 1.18
Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol (1994) 1.18
Serum complement levels in patients with mixed (IgM-IgG) cryoglobulinaemia. Clin Exp Immunol (1966) 1.17
Binding characteristics of a monoclonal beta-endorphin antibody recognizing the N-terminus of opioid peptides. J Neurochem (1983) 1.17
A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol (1998) 1.17
Immunology of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. An update. Ann Intern Med (1987) 1.16
Monoclonal antibody to the message sequence Tyr-Gly-Gly-Phe of opioid peptides exhibits the specificity requirements of mammalian opioid receptors. Proc Natl Acad Sci U S A (1983) 1.14
Complete sequence of HLA-B27 cDNA identified through the characterization of structural markers unique to the HLA-A, -B, and -C allelic series. Proc Natl Acad Sci U S A (1986) 1.13
Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells. J Autoimmun (1989) 1.11
Distribution of cell adhesion molecules (ICAM-1, VCAM-1, ELAM-1) in renal tissue during allograft rejection. Transplantation (1993) 1.11
Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet (1991) 1.11
Suppression of graft versus host reaction by univalent anti-immunoglobulin antibody. Nat New Biol (1971) 1.09
Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol (1993) 1.08
Constitutive monocyte-restricted activity of NF-M, a nuclear factor that binds to a C/EBP motif. J Immunol (1992) 1.08
Downregulation of tumor necrosis factor expression in the human Mono-Mac-6 cell line by lipopolysaccharide. J Leukoc Biol (1989) 1.08
Biosynthesis of complement C4 messenger RNA in normal human kidney. Nephron (1989) 1.06
A subset of human cells isolated and characterized by monoclonal antibodies. Eur J Immunol (1981) 1.06
Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity. Cancer Res (1986) 1.05
A rapid assay for cytotoxicity of unstimulated human monocytes. J Natl Cancer Inst (1984) 1.05
Fas/Apo-1 activates nuclear factor kappa B and induces interleukin-6 production. J Inflamm (1995) 1.05
MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread. Cancer Res (1994) 1.04
The melanoma progression-associated antigen P3.58 is identical to the intercellular adhesion molecule, ICAM-1. Immunobiology (1988) 1.03
Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol (1995) 1.02
Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res (1993) 1.02
Classical pathway of complement activation in normal and diseased human glomeruli. Kidney Int (1989) 1.02
Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol (2001) 1.01
Characteristics of a monoclonal beta-endorphin antibody recognizing the N-terminus of opioid peptides. Life Sci (1983) 1.01
Micrometastasis detection and treatment with monoclonal antibodies. Curr Top Microbiol Immunol (1996) 1.01
Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. J Invest Dermatol (1991) 1.00
Expression of the CD6 T lymphocyte differentiation antigen in normal human brain. J Neuroimmunol (1990) 1.00
Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer. J Clin Oncol (1998) 1.00
Structural characteristics of the 5' region of the human ICAM-1 gene. Immunobiology (1990) 0.99
Zn++ inhibits both tumor necrosis factor-mediated DNA fragmentation and cytolysis. Int J Cancer (1989) 0.99
Inhibition of lipopolysaccharide-induced in vitro desensitization by interferon-gamma. Eur J Immunol (1990) 0.99
Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. Cancer Genet Cytogenet (1996) 0.99
Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. J Clin Oncol (2001) 0.99
Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res (1999) 0.99
Triple immunofluorescence flow cytometry, using whole blood, of CD4+ and CD8+ lymphocytes expressing CD45RO and CD45RA. J Immunol Methods (1993) 0.98
Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia (2003) 0.96
In situ analysis of antigens on malignant and benign cells of the melanocyte lineage. Differential expression of two surface molecules, gp75 and p89. J Exp Med (1985) 0.96
Complement activation in human lymphoid germinal centres. Immunology (1989) 0.95
Monocyte phenotype and function in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders. Scand J Immunol (1987) 0.95
Glycoprotein P3.58, associated with tumor progression in malignant melanoma, is a novel leukocyte activation antigen. Int J Cancer (1988) 0.95
Class II (DR) antigen expression on CD8+ lymphocyte subsets in acquired immune deficiency syndrome (AIDS). J Clin Immunol (1988) 0.95
Infiltrating mononuclear cells in human breast carcinoma: predominance of T4+ monocytic cells in the tumor stroma. Int J Cancer (1985) 0.95
Immunocytochemical detection and phenotypic characterization of micrometastatic tumour cells in bone marrow of patients with prostate cancer. Urol Res (1994) 0.94
Anergic TH1 clones specific for hepatitis B virus (HBV) core peptides are inhibitory to other HBV core-specific CD4+ T cells in vitro. J Virol (1996) 0.94
Differential expression of MHC class II subregion products on bile duct epithelial cells and hepatocytes in patients with primary biliary cirrhosis. Hepatology (1988) 0.93
Deletion of T lymphocytes in human CD4 transgenic mice induced by HIV-gp120 and gp120-specific antibodies from AIDS patients. Eur J Immunol (1994) 0.92
Synergistic effect of tumor necrosis factor-alpha and interferon-gamma on collagen synthesis of human skin fibroblasts in vitro. Exp Cell Res (1989) 0.92
Detection, characterization and tumorigenicity of disseminated tumor cells in human bone marrow. Semin Cancer Biol (1990) 0.91
Direct monoclonal antibody rosetting. An effective method for weak antigen detection and large scale separation of human mononuclear cells. J Immunol Methods (1986) 0.91
Increased antibody titers against mycobacterial heat-shock protein 65 in patients with vasculitis and arteriosclerosis. Int Arch Allergy Immunol (1996) 0.90
Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells. Histochemistry (1993) 0.90
Human T cell differentiation antigens characterizing a cytotoxic/suppressor T cell subset. Hybridoma (1981) 0.90
Letter: Intestinal lymphocytes in Crohn's disease. Lancet (1975) 0.90
Immune response of peripheral blood mononuclear cells to HBx-antigen of hepatitis B virus. Hepatology (1991) 0.89
Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors. J Clin Oncol (1999) 0.89
A novel non-radioactive cellular cytotoxicity test based on the differential assessment of living and killed target and effector cells. J Immunol Methods (1995) 0.89